Segment Reporting (Summary of Net Revenues by Product Segment) (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	$ 56,670	$ 59,366
Finished Pharmaceutical Products
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	55,934	58,554
Finished Pharmaceutical Products | Enoxaparin
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	10,410	18,358
Finished Pharmaceutical Products | Naloxone
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	10,939	10,254
Finished Pharmaceutical Products | Lidocaine
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	8,289	9,908
Finished Pharmaceutical Products | Phytonadione
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	7,886	6,126
Finished Pharmaceutical Products | Epinephrine
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	9,574	4,392
Finished Pharmaceutical Products | Other Finished Pharmaceutical Products
Segment Reporting Information, Revenue for Reportable Segment [Abstract]
Net Revenue	$ 8,836	$ 9,516